AI assistant
GlaxoSmithKline PLC — Director's Dealing 2018
Oct 17, 2018
5262_dirs_2018-10-17_064b6096-dd07-4a4a-a9aa-3a2f606597ca.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4029E
GlaxoSmithKline PLC
17 October 2018
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 208 |
| £14.516 | 226 |
| £14.516 | 792 |
| £14.516 | 207 |
| £14.516 | 226 |
d)
Aggregated information
Aggregated volume Price
1659
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 141 |
| £14.516 | 117 |
| £14.516 | 167 |
| £14.516 | 117 |
d)
Aggregated information
Aggregated volume Price
543
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 274 |
| £14.516 | 205 |
| £14.516 | 560 |
| £14.516 | 274 |
| £14.516 | 205 |
d)
Aggregated information
Aggregated volume Price
1518
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 101 |
| £14.516 | 74 |
| £14.516 | 88 |
| £14.516 | 101 |
| £14.516 | 74 |
d)
Aggregated information
Aggregated volume Price
438
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $38.47 | 84 |
| $38.47 | 82 |
d)
Aggregated information
Aggregated volume Price
166
$38.47
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 159 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 129 |
| £14.516 | 93 |
| £14.516 | 162 |
| £14.516 | 93 |
| £14.516 | 129 |
d)
Aggregated information
Aggregated volume Price
606
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell
b)
Position/status
Chief Digital & Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $38.47 | 28 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 189 |
| £14.516 | 141 |
| £14.516 | 177 |
| £14.516 | 189 |
| £14.516 | 141 |
d)
Aggregated information
Aggregated volume Price
837
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £14.516 | 115 |
| £14.516 | 88 |
| £14.516 | 110 |
d)
Aggregated information
Aggregated volume Price
313
£14.516
e)
Date of the transaction
2018-10-12
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHQDLFFVBFEFBX